AGENUS INC Research and Development Expense
AGENUS INC (AGEN) reported Research and Development Expense of $14.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- AGENUS INC research and development expense for the quarter ending 2026-06-30 was $14.76M, a 44.74% decline year-over-year.
- AGENUS INC research and development expense for the quarter ending 2026-03-31 was $11.82M, a 45.07% decline year-over-year.
- AGENUS INC research and development expense for the quarter ending 2025-12-31 was $7.51M, a 77.76% decline year-over-year.
- AGENUS INC research and development expense for the quarter ending 2025-09-30 was $23.60M, a 42.53% decline year-over-year.
- AGENUS INC research and development expense for fiscal 2025 was $79.34M, a 48.99% decline from fiscal 2024.
- AGENUS INC research and development expense for fiscal 2024 was $155.53M, a 33.70% decline from fiscal 2023.
- AGENUS INC research and development expense for fiscal 2023 was $234.57M, a 25.65% increase from fiscal 2022.
- AGENUS INC research and development expense for fiscal 2022 was $186.69M, a 4.53% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.76M 10-Q · filed 2026-08-07 | $26.58M 10-Q · filed 2026-08-07 | $34.09M derived: sum of 3 quarters · filed 2026-08-07 | $57.69M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $11.82M 10-Q · filed 2026-05-11 | $19.33M derived: sum of 2 quarters · filed 2026-05-11 | $42.93M derived: sum of 3 quarters · filed 2026-05-11 | $69.64M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $31.11M derived: sum of 2 quarters · filed 2026-03-16 | $57.82M derived: sum of 3 quarters · filed 2026-08-07 | $79.34M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $23.60M 10-Q · filed 2025-11-10 | $50.31M derived: sum of 2 quarters · filed 2026-08-07 | $71.83M 10-Q · filed 2025-11-10 | $105.60M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $26.71M 10-Q · filed 2026-08-07 | $48.23M 10-Q · filed 2026-08-07 | $82.01M derived: sum of 3 quarters · filed 2026-08-07 | $123.06M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $21.52M 10-Q · filed 2026-05-11 | $55.30M derived: sum of 2 quarters · filed 2026-05-11 | $96.36M derived: sum of 3 quarters · filed 2026-05-11 | $133.13M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $33.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $74.83M derived: sum of 2 quarters · filed 2026-03-16 | $111.60M derived: sum of 3 quarters · filed 2026-03-16 | $155.53M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $41.06M 10-Q · filed 2025-11-10 | $77.83M derived: sum of 2 quarters · filed 2025-11-10 | $121.75M 10-Q · filed 2025-11-10 | $188.48M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-06-30 | $36.77M 10-Q · filed 2025-08-11 | $80.70M 10-Q · filed 2025-08-11 | $147.42M derived: sum of 3 quarters · filed 2026-03-16 | $198.86M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-03-31 | $43.92M 10-Q · filed 2025-05-12 | $110.65M derived: sum of 2 quarters · filed 2026-03-16 | $162.09M derived: sum of 3 quarters · filed 2026-03-16 | $221.38M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $66.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $118.17M derived: sum of 2 quarters · filed 2026-03-16 | $177.45M derived: sum of 3 quarters · filed 2026-03-16 | $234.57M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $51.44M 10-Q · filed 2024-11-12 | $110.73M derived: sum of 2 quarters · filed 2024-11-12 | $167.85M 10-Q · filed 2024-11-12 | $221.13M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $59.28M 10-Q · filed 2024-08-08 | $116.40M 10-Q · filed 2024-08-08 | $169.68M derived: sum of 3 quarters · filed 2025-03-17 | $215.69M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $57.12M 10-Q · filed 2024-05-07 | $110.40M derived: sum of 2 quarters · filed 2025-03-17 | $156.41M derived: sum of 3 quarters · filed 2025-03-17 | $201.37M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | $53.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $99.29M derived: sum of 2 quarters · filed 2025-03-17 | $144.25M derived: sum of 3 quarters · filed 2025-03-17 | $186.69M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $46.01M 10-Q · filed 2023-11-09 | $90.97M derived: sum of 2 quarters · filed 2023-11-09 | $133.41M 10-Q · filed 2023-11-09 | $186.90M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | $44.96M 10-Q · filed 2023-08-08 | $87.40M 10-Q · filed 2023-08-08 | $140.89M derived: sum of 3 quarters · filed 2024-03-14 | $183.82M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | $42.44M 10-Q · filed 2023-05-09 | $95.93M derived: sum of 2 quarters · filed 2024-03-14 | $138.87M derived: sum of 3 quarters · filed 2024-03-14 | $184.37M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $53.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $96.42M derived: sum of 2 quarters · filed 2024-03-14 | $141.93M derived: sum of 3 quarters · filed 2024-03-14 | $178.61M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $42.94M 10-Q · filed 2022-11-08 | $88.44M derived: sum of 2 quarters · filed 2022-11-08 | $125.12M 10-Q · filed 2022-11-08 | $160.69M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-06-30 | $45.51M 10-Q · filed 2022-08-09 | $82.18M 10-Q · filed 2022-08-09 | $117.75M derived: sum of 3 quarters · filed 2023-03-16 | $149.89M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-03-31 | $36.68M 10-Q · filed 2022-05-10 | $72.25M derived: sum of 2 quarters · filed 2023-03-16 | $104.38M derived: sum of 3 quarters · filed 2023-03-16 | $142.93M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2020-12-31 | $35.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $67.70M derived: sum of 2 quarters · filed 2023-03-16 | $106.25M derived: sum of 3 quarters · filed 2023-03-16 | $142.62M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $32.13M 10-Q · filed 2021-11-09 | $70.68M derived: sum of 2 quarters · filed 2021-11-09 | $107.05M 10-Q · filed 2021-11-09 | $143.88M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $38.55M 10-Q · filed 2021-08-09 | $74.91M 10-Q · filed 2021-08-09 | $111.75M derived: sum of 3 quarters · filed 2022-03-01 | $157.88M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $36.36M 10-Q · filed 2021-05-07 | $73.20M derived: sum of 2 quarters · filed 2022-03-01 | $119.33M derived: sum of 3 quarters · filed 2022-03-01 | $164.57M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $36.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $82.97M derived: sum of 2 quarters · filed 2022-03-01 | $128.21M derived: sum of 3 quarters · filed 2022-03-01 | $168.34M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $46.13M 10-Q · filed 2020-11-09 | $91.38M derived: sum of 2 quarters · filed 2020-11-09 | $131.51M 10-Q · filed 2020-11-09 | $167.54M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-06-30 | $45.24M 10-Q · filed 2020-08-10 | $85.37M 10-Q · filed 2020-08-10 | $121.40M derived: sum of 3 quarters · filed 2021-03-16 | $151.26M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-03-31 | $40.13M 10-Q · filed 2020-05-11 | $76.16M derived: sum of 2 quarters · filed 2021-03-16 | $106.02M derived: sum of 3 quarters · filed 2021-03-16 | $135.29M derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2018-12-31 | $36.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $65.89M derived: sum of 2 quarters · filed 2021-03-16 | $95.16M derived: sum of 3 quarters · filed 2021-03-16 | $124.60M 10-K · filed 2021-03-16 | $124.60M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $29.85M 10-Q · filed 2019-11-07 | $29.85M 10-Q · filed 2018-11-07 | $59.13M derived: sum of 2 quarters · filed 2019-11-07 | $88.57M 10-Q · filed 2019-11-07 | $88.57M 10-Q · filed 2018-11-07 | $120.44M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-06-30 | $29.27M 10-Q · filed 2019-08-09 | $29.27M 10-Q · filed 2018-08-09 | $58.72M 10-Q · filed 2019-08-09 | $58.71M 10-Q · filed 2018-08-09 | $90.59M derived: sum of 3 quarters · filed 2020-03-16 | $116.38M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | $29.44M 10-Q · filed 2019-05-10 | $29.44M 10-Q · filed 2018-05-10 | $61.31M derived: sum of 2 quarters · filed 2020-03-16 | $87.10M derived: sum of 3 quarters · filed 2020-03-16 | $112.93M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2017-12-31 | $31.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $57.66M derived: sum of 2 quarters · filed 2020-03-16 | $83.49M derived: sum of 3 quarters · filed 2020-03-16 | $116.13M 10-K · filed 2020-03-16 | $116.13M 10-K · filed 2018-03-16 | |||
| 2017-09-30 | $25.79M 10-Q · filed 2018-11-07 | $51.61M derived: sum of 2 quarters · filed 2018-11-07 | $84.25M 10-Q · filed 2018-11-07 | $110.24M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $25.82M 10-Q · filed 2018-08-09 | $58.46M 10-Q · filed 2018-08-09 | $84.45M derived: sum of 3 quarters · filed 2019-03-18 | $106.04M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $32.64M 10-Q · filed 2018-05-10 | $58.62M derived: sum of 2 quarters · filed 2019-03-18 | $80.21M derived: sum of 3 quarters · filed 2019-03-18 | $102.57M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $25.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $47.57M derived: sum of 2 quarters · filed 2019-03-18 | $69.93M derived: sum of 3 quarters · filed 2019-03-18 | $94.97M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $21.59M 10-Q · filed 2017-11-07 | $43.95M derived: sum of 2 quarters · filed 2017-11-07 | $68.99M 10-Q · filed 2017-11-07 | $86.94M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-06-30 | $22.36M 10-Q · filed 2017-08-07 | $47.40M 10-Q · filed 2017-08-07 | $65.35M derived: sum of 3 quarters · filed 2018-03-16 | $83.85M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-03-31 | $25.04M 10-Q · filed 2017-05-04 | $42.99M derived: sum of 2 quarters · filed 2018-03-16 | $61.49M derived: sum of 3 quarters · filed 2018-03-16 | $86.26M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2015-12-31 | $17.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $36.45M derived: sum of 2 quarters · filed 2018-03-16 | $61.22M derived: sum of 3 quarters · filed 2018-03-16 | $70.44M 10-K · filed 2018-03-16 | ||||
| 2015-09-30 | $18.50M 10-Q · filed 2016-11-09 | $43.28M derived: sum of 2 quarters · filed 2016-11-09 | $52.50M 10-Q · filed 2016-11-09 | $59.86M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $24.77M 10-Q · filed 2016-08-04 | $33.99M 10-Q · filed 2016-08-04 | $41.36M derived: sum of 3 quarters · filed 2017-03-16 | $46.65M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $9.22M 10-Q · filed 2016-05-09 | $16.59M derived: sum of 2 quarters · filed 2017-03-16 | $21.87M derived: sum of 3 quarters · filed 2017-03-16 | $27.10M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | $7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $12.65M derived: sum of 2 quarters · filed 2017-03-16 | $17.88M derived: sum of 3 quarters · filed 2017-03-16 | $22.35M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $5.28M 10-Q · filed 2015-11-04 | $10.51M derived: sum of 2 quarters · filed 2015-11-04 | $14.98M 10-Q · filed 2015-11-04 | $18.22M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $5.22M 10-Q · filed 2015-08-03 | $9.70M 10-Q · filed 2015-08-03 | $12.94M derived: sum of 3 quarters · filed 2016-03-15 | $16.83M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $4.47M 10-Q · filed 2015-05-01 | $7.71M derived: sum of 2 quarters · filed 2016-03-15 | $11.61M derived: sum of 3 quarters · filed 2016-03-15 | $14.92M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $7.13M derived: sum of 2 quarters · filed 2016-03-15 | $10.45M derived: sum of 3 quarters · filed 2016-03-15 | $13.01M 10-K · filed 2016-03-15 | ||||
| 2013-09-30 | $3.89M 10-Q · filed 2014-10-31 | -$3.89M 10-Q · filed 2013-11-08 | $7.21M derived: sum of 2 quarters · filed 2014-10-31 | $9.76M 10-Q · filed 2014-10-31 | -$9.76M 10-Q · filed 2013-11-08 | $28.52M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-06-30 | $3.32M 10-Q · filed 2014-08-01 | -$3.32M 10-Q · filed 2013-08-09 | $5.87M 10-Q · filed 2014-08-01 | -$5.87M 10-Q · filed 2013-08-09 | $24.63M derived: sum of 3 quarters · filed 2015-03-16 | $22.02M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-03-31 | $2.55M 10-Q · filed 2014-05-09 | -$2.55M 10-Q · filed 2013-05-10 | $21.31M derived: sum of 2 quarters · filed 2015-03-16 | $18.71M derived: sum of 3 quarters · filed 2015-03-16 | $15.80M derived: sum of 4 quarters · filed 2015-03-16 | |||
| 2012-12-31 | $18.76M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $16.15M derived: sum of 2 quarters · filed 2015-03-16 | $13.24M derived: sum of 3 quarters · filed 2015-03-16 | $10.56M 10-K · filed 2015-03-16 | ||||
| 2012-09-30 | -$2.61M 10-Q · filed 2013-11-08 | $2.61M 10-Q · filed 2012-11-07 | -$5.52M derived: sum of 2 quarters · filed 2013-11-08 | -$8.19M 10-Q · filed 2013-11-08 | $8.19M 10-Q · filed 2012-11-07 | -$5.34M derived: sum of 4 quarters · filed 2014-03-07 | ||
| 2012-06-30 | -$2.91M 10-Q · filed 2013-08-09 | $2.91M 10-Q · filed 2012-08-08 | -$5.59M 10-Q · filed 2013-08-09 | $5.59M 10-Q · filed 2012-08-08 | -$2.73M derived: sum of 3 quarters · filed 2014-03-07 | -$204.54K derived: sum of 4 quarters · filed 2014-03-07 | ||
| 2012-03-31 | -$2.68M 10-Q · filed 2013-05-10 | $2.68M 10-Q · filed 2012-05-09 | $178.93K derived: sum of 2 quarters · filed 2014-03-07 | $2.71M derived: sum of 3 quarters · filed 2014-03-07 | $5.53M derived: sum of 4 quarters · filed 2014-03-07 | |||
| 2011-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $5.38M derived: sum of 2 quarters · filed 2014-03-07 | $8.21M derived: sum of 3 quarters · filed 2014-03-07 | $11.02M 10-K · filed 2014-03-07 | ||||
| 2011-09-30 | $2.53M 10-Q · filed 2012-11-07 | $5.35M derived: sum of 2 quarters · filed 2012-11-07 | $8.17M 10-Q · filed 2012-11-07 | $10.96M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-06-30 | $2.82M 10-Q · filed 2012-08-08 | $5.64M 10-Q · filed 2012-08-08 | $8.43M derived: sum of 3 quarters · filed 2013-03-18 | $11.26M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-03-31 | $2.82M 10-Q · filed 2012-05-09 | $5.61M derived: sum of 2 quarters · filed 2013-03-18 | $8.43M derived: sum of 3 quarters · filed 2013-03-18 | $11.06M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2010-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $5.62M derived: sum of 2 quarters · filed 2013-03-18 | $8.25M derived: sum of 3 quarters · filed 2013-03-18 | $12.88M 10-K · filed 2013-03-18 | ||||
| 2010-09-30 | $2.82M 10-Q · filed 2011-11-04 | $5.45M derived: sum of 2 quarters · filed 2011-11-04 | $10.08M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $2.63M 10-Q · filed 2011-08-05 | $7.26M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $16.90M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |